Antibody-Drug Conjugates in Breast Cancer: A Comprehensive Review of How to Selectively Deliver Payloads

Mariana Ribeiro Monteiro,1,2 Natalia Cristina Cardoso Nunes,3 Aumilto Augusto da Silva Junior,4 Angelo Bezerra de Souza Fêde,5 Gustavo de Oliveira Bretas,6 Cristiano de Pádua Souza,7 Max Mano,8 Jesse Lopes da Silva6,9,10 1Instituto Americas, São Paulo, Brazil; 2Hospital Samaritano, São Paulo, Brazil...

Full description

Bibliographic Details
Main Authors: Monteiro MR, Nunes NCC, Junior AADS, Fêde ABDS, Bretas GDO, Souza CDP, Mano M, da Silva JL
Format: Article
Language:English
Published: Dove Medical Press 2024-02-01
Series:Breast Cancer: Targets and Therapy
Subjects:
Online Access:https://www.dovepress.com/antibody-drug-conjugates-in-breast-cancer-a-comprehensive-review-of-ho-peer-reviewed-fulltext-article-BCTT
_version_ 1827330854861406208
author Monteiro MR
Nunes NCC
Junior AADS
Fêde ABDS
Bretas GDO
Souza CDP
Mano M
da Silva JL
author_facet Monteiro MR
Nunes NCC
Junior AADS
Fêde ABDS
Bretas GDO
Souza CDP
Mano M
da Silva JL
author_sort Monteiro MR
collection DOAJ
description Mariana Ribeiro Monteiro,1,2 Natalia Cristina Cardoso Nunes,3 Aumilto Augusto da Silva Junior,4 Angelo Bezerra de Souza Fêde,5 Gustavo de Oliveira Bretas,6 Cristiano de Pádua Souza,7 Max Mano,8 Jesse Lopes da Silva6,9,10 1Instituto Americas, São Paulo, Brazil; 2Hospital Samaritano, São Paulo, Brazil; 3Instituto Americas, Rio de Janeiro, Brazil; 4Hospital Santa Catarina Paulista, São Paulo, Brazil; 5DASA Oncologia, São Paulo, Brazil; 6Grupo Oncoclínicas, Rio de Janeiro, Brazil; 7Hospital do Câncer de Barretos, São Paulo, Brazil; 8Grupo Oncoclínicas, São Paulo, Brazil; 9Divisão de Pesquisa Clínica e Desenvolvimento Tecnológico, Instituto Nacional do Câncer, Rio de Janeiro, Brazil; 10Hospital da Força Aérea do Galeão, Rio de Janeiro, BrazilCorrespondence: Mariana Ribeiro Monteiro, Email marianarmonteiro@hotmail.comAbstract: Antibody-drug conjugates (ADCs) have surfaced as a promising group of anticancer agents employing the precise targeting capacity of monoclonal antibodies to transport highly effective cytotoxic payloads. Compared to conventional chemotherapy, they aim to selectively eradicate cancer cells while minimizing off-target toxicity on healthy tissues. An increasing body of evidence has provided support for the efficacy of ADCs in treating breast cancer across various contexts and tumor subtypes, resulting in significant changes in clinical practice. Nevertheless, unlocking the full potential of these therapeutic agents demands innovative molecular designs to address complex clinical challenges, including drug resistance, tumor heterogeneity, and treatment-related adverse events. This thorough review provides an in-depth analysis of the clinical data on ADCs, offering crucial insights from pivotal clinical trials that assess the efficacy of ADCs in diverse breast cancer settings. This aids in providing a comprehensive understanding of the current state of ADCs in breast cancer therapy, while also providing valuable perspectives for the future.Keywords: breast cancer, cancer therapy, target therapy, antibody–drug conjugates, ADCs
first_indexed 2024-03-07T16:24:24Z
format Article
id doaj.art-3c520957b17c4872be92927a6bcdafcc
institution Directory Open Access Journal
issn 1179-1314
language English
last_indexed 2024-03-07T16:24:24Z
publishDate 2024-02-01
publisher Dove Medical Press
record_format Article
series Breast Cancer: Targets and Therapy
spelling doaj.art-3c520957b17c4872be92927a6bcdafcc2024-03-03T18:36:49ZengDove Medical PressBreast Cancer: Targets and Therapy1179-13142024-02-01Volume 16517090792Antibody-Drug Conjugates in Breast Cancer: A Comprehensive Review of How to Selectively Deliver PayloadsMonteiro MRNunes NCCJunior AADSFêde ABDSBretas GDOSouza CDPMano Mda Silva JLMariana Ribeiro Monteiro,1,2 Natalia Cristina Cardoso Nunes,3 Aumilto Augusto da Silva Junior,4 Angelo Bezerra de Souza Fêde,5 Gustavo de Oliveira Bretas,6 Cristiano de Pádua Souza,7 Max Mano,8 Jesse Lopes da Silva6,9,10 1Instituto Americas, São Paulo, Brazil; 2Hospital Samaritano, São Paulo, Brazil; 3Instituto Americas, Rio de Janeiro, Brazil; 4Hospital Santa Catarina Paulista, São Paulo, Brazil; 5DASA Oncologia, São Paulo, Brazil; 6Grupo Oncoclínicas, Rio de Janeiro, Brazil; 7Hospital do Câncer de Barretos, São Paulo, Brazil; 8Grupo Oncoclínicas, São Paulo, Brazil; 9Divisão de Pesquisa Clínica e Desenvolvimento Tecnológico, Instituto Nacional do Câncer, Rio de Janeiro, Brazil; 10Hospital da Força Aérea do Galeão, Rio de Janeiro, BrazilCorrespondence: Mariana Ribeiro Monteiro, Email marianarmonteiro@hotmail.comAbstract: Antibody-drug conjugates (ADCs) have surfaced as a promising group of anticancer agents employing the precise targeting capacity of monoclonal antibodies to transport highly effective cytotoxic payloads. Compared to conventional chemotherapy, they aim to selectively eradicate cancer cells while minimizing off-target toxicity on healthy tissues. An increasing body of evidence has provided support for the efficacy of ADCs in treating breast cancer across various contexts and tumor subtypes, resulting in significant changes in clinical practice. Nevertheless, unlocking the full potential of these therapeutic agents demands innovative molecular designs to address complex clinical challenges, including drug resistance, tumor heterogeneity, and treatment-related adverse events. This thorough review provides an in-depth analysis of the clinical data on ADCs, offering crucial insights from pivotal clinical trials that assess the efficacy of ADCs in diverse breast cancer settings. This aids in providing a comprehensive understanding of the current state of ADCs in breast cancer therapy, while also providing valuable perspectives for the future.Keywords: breast cancer, cancer therapy, target therapy, antibody–drug conjugates, ADCshttps://www.dovepress.com/antibody-drug-conjugates-in-breast-cancer-a-comprehensive-review-of-ho-peer-reviewed-fulltext-article-BCTTbreast cancercancer therapytarget therapyantibody–drug conjugatesadcs
spellingShingle Monteiro MR
Nunes NCC
Junior AADS
Fêde ABDS
Bretas GDO
Souza CDP
Mano M
da Silva JL
Antibody-Drug Conjugates in Breast Cancer: A Comprehensive Review of How to Selectively Deliver Payloads
Breast Cancer: Targets and Therapy
breast cancer
cancer therapy
target therapy
antibody–drug conjugates
adcs
title Antibody-Drug Conjugates in Breast Cancer: A Comprehensive Review of How to Selectively Deliver Payloads
title_full Antibody-Drug Conjugates in Breast Cancer: A Comprehensive Review of How to Selectively Deliver Payloads
title_fullStr Antibody-Drug Conjugates in Breast Cancer: A Comprehensive Review of How to Selectively Deliver Payloads
title_full_unstemmed Antibody-Drug Conjugates in Breast Cancer: A Comprehensive Review of How to Selectively Deliver Payloads
title_short Antibody-Drug Conjugates in Breast Cancer: A Comprehensive Review of How to Selectively Deliver Payloads
title_sort antibody drug conjugates in breast cancer a comprehensive review of how to selectively deliver payloads
topic breast cancer
cancer therapy
target therapy
antibody–drug conjugates
adcs
url https://www.dovepress.com/antibody-drug-conjugates-in-breast-cancer-a-comprehensive-review-of-ho-peer-reviewed-fulltext-article-BCTT
work_keys_str_mv AT monteiromr antibodydrugconjugatesinbreastcanceracomprehensivereviewofhowtoselectivelydeliverpayloads
AT nunesncc antibodydrugconjugatesinbreastcanceracomprehensivereviewofhowtoselectivelydeliverpayloads
AT junioraads antibodydrugconjugatesinbreastcanceracomprehensivereviewofhowtoselectivelydeliverpayloads
AT fedeabds antibodydrugconjugatesinbreastcanceracomprehensivereviewofhowtoselectivelydeliverpayloads
AT bretasgdo antibodydrugconjugatesinbreastcanceracomprehensivereviewofhowtoselectivelydeliverpayloads
AT souzacdp antibodydrugconjugatesinbreastcanceracomprehensivereviewofhowtoselectivelydeliverpayloads
AT manom antibodydrugconjugatesinbreastcanceracomprehensivereviewofhowtoselectivelydeliverpayloads
AT dasilvajl antibodydrugconjugatesinbreastcanceracomprehensivereviewofhowtoselectivelydeliverpayloads